{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Di Federico A"],"pubmed_abstract":["Epidermal growth factor receptor (<i>EGFR</i>) gene fusions represent an extremely rare aberration, occurring in approximately 0.05-0.13% non-small cell lung cancer (NSCLC) patients. <i>RAD51</i> is the most frequently involved partner gene in <i>EGFR</i> fusions, but other fusion partner genes have been described. To date, a considerable number of next-generation sequencing (NGS) panels still cannot detect these alterations due to the position of the breakpoint site, mainly involving intron 24 of <i>EGFR</i>. Current evidences show that such gene alteration is more likely to occur in lung adenocarcinomas of young, female, non-smoker patients. Also, brain metastases are frequently reported in these patients. Only very few cases in literature described clinical characteristics and outcomes "],"journal":["Translational lung cancer research"],"pagination":["497-503"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8988076"],"repository":["biostudies-literature"],"pubmed_title":["<i>EGFR</i>-<i>RAD51</i> gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature."],"pmcid":["PMC8988076"],"pubmed_authors":["Di Federico A","Gelsomino F","De Giglio A","Palladini A","Giusti R","Ardizzoni A","Piras M","Filetti M"],"additional_accession":[]},"is_claimable":false,"name":"<i>EGFR</i>-<i>RAD51</i> gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature.","description":"Epidermal growth factor receptor (<i>EGFR</i>) gene fusions represent an extremely rare aberration, occurring in approximately 0.05-0.13% non-small cell lung cancer (NSCLC) patients. <i>RAD51</i> is the most frequently involved partner gene in <i>EGFR</i> fusions, but other fusion partner genes have been described. To date, a considerable number of next-generation sequencing (NGS) panels still cannot detect these alterations due to the position of the breakpoint site, mainly involving intron 24 of <i>EGFR</i>. Current evidences show that such gene alteration is more likely to occur in lung adenocarcinomas of young, female, non-smoker patients. Also, brain metastases are frequently reported in these patients. Only very few cases in literature described clinical characteristics and outcomes ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T10:45:19.906Z","creation":"2025-04-04T10:45:19.906Z"},"accession":"S-EPMC8988076","cross_references":{"pubmed":["35399574"],"doi":["10.21037/tlcr-21-888"]}}